SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma gains on getting RBI’s approval to hike FIIs limit

07 Sep 2015 Evaluate

Natco Pharma is currently trading at Rs. 2258.00, up by 7.75 points or 0.34% from its previous closing of Rs. 2250.25 on the BSE.

The scrip opened at Rs. 2299.00 and has touched a high and low of Rs. 2299.00 and Rs. 2254.00 respectively. So far 3331 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 2709.00 on 07-Apr-2015 and a 52 week low of Rs. 1245.40 on 20-Oct-2014.

Last one week high and low of the scrip stood at Rs. 2315.20 and Rs. 2220.00 respectively. The current market cap of the company is Rs. 7504.43 crore.

The promoters holding in the company stood at 53.76% while Institutions and Non-Institutions held 15.02% and 31.23% respectively.

Reserve Bank of India (RBI) has allowed Foreign Institutional Investors (FIIs)/Registered Foreign Portfolios Investors (RFPIs) to buy up to 31.50% of the paid up capital of Natco Pharma. Earlier, the FII limit in the company was 24%. The purchases could be made through primary market and stock exchanges.

The company has passed resolutions at its board of directors’ level and a special resolution by the shareholders, agreeing for enhancing the limit for the purchase of its equity shares and convertible debentures by FIIs/RFPIs.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

1093.90 22.90 (2.14%)
24-Apr-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1618.50
Dr. Reddys Lab 1312.40
Cipla 1295.00
Zydus Lifesciences 930.00
Lupin 2285.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×